ReviewJournal of fungi (Basel, Switzerland)2020
Nikkomycin Z-Ready to Meet the Promise?
Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 72 citations in OpenAlex.
- Cryo-EM structures of Candida albicans chitin synthase Chs1 reveal a druggable translocation channel.Nature microbiology · 2026Article
- Beyond Fungitoxicity: Recent Achievements in Targeted Fungicide Discovery.Journal of fungi (Basel, Switzerland) · 2026Review
- Killing ofMicrobiology (Reading, England) · 2026Article
- Antifungal peptides: From modes of action to synergistic and immunologic potential.Cell stress · 2026Article
- Drug Discovery and Repurposing forJournal of fungi (Basel, Switzerland) · 2025Review
- Fungal Chitin Synthases: Structure, Function, and Regulation.Journal of fungi (Basel, Switzerland) · 2025Review
- Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects.Acta pharmaceutica Sinica. B · 2025Review
- Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025Review
- Antifungal activity of ETD151 against azole-susceptible and -resistantCurrent research in microbial sciences · 2025Article
- The progress and future of the treatment of Candida albicans infections based on nanotechnology.Journal of nanobiotechnology · 2024Review
- Marine-Derived Metabolites Act as Promising Antifungal Agents.Marine drugs · 2024Review
- Interplay of Cytokines and Chemokines in Aspergillosis.Journal of fungi (Basel, Switzerland) · 2024Review
- Advancements and challenges in antifungal therapeutic development.Clinical microbiology reviews · 2024Review
- Breaking down barriers: comprehensive functional analysis of the Aspergillus niger chitin synthase repertoire.Fungal biology and biotechnology · 2024Article
- Innovations in Antifungal Drug Discovery among Cell Envelope Synthesis Enzymes through Structural Insights.Journal of fungi (Basel, Switzerland) · 2024Review
- Old and new strategies in therapy and diagnosis against fungal infections.Applied microbiology and biotechnology · 2024Review
- Intestinal Mucosal Immune Barrier: A Powerful Firewall Against Severe Acute Pancreatitis-Associated Acute Lung Injury via the Gut-Lung Axis.Journal of inflammation research · 2024Review
- Synergy In Vitro of Nikkomycin Z with Azole Against the Invasive Form of Candida albicans.Mycopathologia · 2023Article
- Review
- In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against FourPharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nikkomycin Z (NikZ) has fungicidal activity against some fungal species which currently requires patients to endure chronic therapy, sometimes for years. This review highlights reports of NikZ activity against fungal species for which current therapeutics are still inadequate, as a potential roadmap for continuing investigation. The possibility of faster and more complete clinical resolution by using NikZ has attracted scientific attention for decades. NikZ inhibits chitin structure formation, which is important for fungi, but not found in mammals. NikZ raised no safety concerns in a human Phase 1 trial or in extensive toxicology studies. NikZ showed strong clinical benefit in dogs with natural
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.